- Home
- MDGL vs AXSM Comparison
MDGL vs AXSM Comparison
Compare MDGL & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- AXSM
- Stock Information
- Founded
- MDGL 2011
- AXSM 2012
- Country
- MDGL United States
- AXSM United States
- Employees
- MDGL N/A
- AXSM N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- MDGL Health Care
- AXSM Health Care
- Exchange
- MDGL Nasdaq
- AXSM Nasdaq
- Market Cap
- MDGL 6.1B
- AXSM 5.1B
- IPO Year
- MDGL N/A
- AXSM 2015
- Fundamental
- Price
- MDGL $314.31
- AXSM $108.98
- Analyst Decision
- MDGL Strong Buy
- AXSM Strong Buy
- Analyst Count
- MDGL 9
- AXSM 17
- Target Price
- MDGL $420.63
- AXSM $171.65
- AVG Volume (30 Days)
- MDGL 282.4K
- AXSM 636.2K
- Earning Date
- MDGL 08-06-2025
- AXSM 08-04-2025
- Dividend Yield
- MDGL N/A
- AXSM N/A
- EPS Growth
- MDGL N/A
- AXSM N/A
- EPS
- MDGL N/A
- AXSM N/A
- Revenue
- MDGL $317,383,000.00
- AXSM $432,157,000.00
- Revenue This Year
- MDGL $286.17
- AXSM $62.84
- Revenue Next Year
- MDGL $64.17
- AXSM $60.02
- P/E Ratio
- MDGL N/A
- AXSM N/A
- Revenue Growth
- MDGL N/A
- AXSM 72.16
- 52 Week Low
- MDGL $200.63
- AXSM $72.21
- 52 Week High
- MDGL $377.46
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- MDGL 64.53
- AXSM 56.00
- Support Level
- MDGL $284.02
- AXSM $102.26
- Resistance Level
- MDGL $311.21
- AXSM $114.66
- Average True Range (ATR)
- MDGL 11.94
- AXSM 3.49
- MACD
- MDGL 2.74
- AXSM 0.92
- Stochastic Oscillator
- MDGL 100.00
- AXSM 61.89
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.